FDA approves new macular degeneration treatment

Share this article:

The Food and Drug Administration has approved a new drug for the treatment of the wet form of age-related macular degeneration, called Eylea. Macular degeneration is the leading cause of severe vision loss in the elderly.

Eylea, which is manufactured by Regeneron Pharmaceuticals, is a slightly less expensive treatment, costing $1,850 per injection, versus $1,950 for Genentech's Lucentis.

Both Lucentis and Eylea are still more expensive than the cancer drug Avastin, also made by Genentech. Avastin, which was recently pulled by the FDA as a breast cancer treatment option, is used as an off-label drug to treat macular degeneration, and accounts for over half of that market, The New York Times reports. Avastin costs only $50 per dose, but has been hampered recently due to reports that tainted vials of the drug infected users with Streptococcus endophthalmitis.

 

Share this article:

More in News

Proposed managed care rule could accelerate shift away from nursing home care, official suggests

Proposed managed care rule could accelerate shift away ...

Proposed regulations slated for early 2015 likely will affect how Medicaid managed care balances home- versus facility-based long-term care, news sources reported Wednesday.

Assisted living residents say 'homelike' setting not so important

Contrary to conventional wisdom, assisted living residents might not place a high value on how "homelike" their surroundings are, suggest findings out of St. Catherine University in St. Paul, MN.

Adjust residents' hearing aids before they listen to music, researcher advises

Nursing home residents might get more enjoyment and therapeutic value out of music if they change hearing aid settings, recently published findings suggest.